Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 3, 2006. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than general financial performance.
Material Changes
A re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("The Plan") resulted in an increase in the notional allocation of Ordinary Share ADRs. This transaction occurred on December 30, 2005, at a price of $50.48 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The document is a compliance notification under Disclosure Rule 3.1.4R(1)(a) regarding the transaction of Dr. R Greig.
Investor Verification Points
- Verify the specific details of the notional allocation increase for Dr. R Greig within the US Retirement Savings Plan.
- Confirm the share price of $50.48 per ADR used for the December 30, 2005 transaction.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.